Evidence map›Paper›PMID 42380307›Full record

ArticleEMBO molecular medicine2026

Impaired gephyrin G-domain trimerization and phase separation in a patient with developmental epileptic encephalopathy.

Emanuel H W Bruckisch, Marcelo de Melo Aragão, Thais Dos Santos Rohde, Ann-Kathrin Huber, Mateus de Oliveira Torres, Günter Schwarz, Filip Liebsch

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emanuel H W BruckischInstitute of Biochemistry, Department of Chemistry, University of Cologne, 50674, Cologne, Germany.ORCID http://orcid.org/0000-0003-2551-5919
Marcelo de Melo AragãoDepartment of Neurology & Neurosurgery, University Hospital São Paulo, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Thais Dos Santos RohdeDepartment of Neurology & Neurosurgery, University Hospital São Paulo, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Ann-Kathrin HuberInstitute of Biochemistry, Department of Chemistry, University of Cologne, 50674, Cologne, Germany.
Mateus de Oliveira TorresDepartment of Neurology & Neurosurgery, University Hospital São Paulo, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
Günter SchwarzInstitute of Biochemistry, Department of Chemistry, University of Cologne, 50674, Cologne, Germany. gschwarz@uni-koeln.de.ORCID http://orcid.org/0000-0002-2118-9338
Filip LiebschInstitute of Biochemistry, Department of Chemistry, University of Cologne, 50674, Cologne, Germany. f.liebsch@uni-koeln.de.ORCID http://orcid.org/0000-0002-0955-8065

Funding

Deutsche Forschungsgemeinschaft (DFG) RTG2550/1736 project ID 411422114
6 · The paper itself

Abstract

Epilepsy, a common neurological disorder is frequently linked to genetic variants in synaptic proteins. Here, we describe a de novo pathogenic missense variant in the gephyrin G-domain (G134R) identified in an individual with developmental delay, epileptic seizures, microcephaly, dysmorphic features and short stature. Functional analyses reveal that G134R disrupts higher-order oligomerization, leading to impaired liquid-liquid phase separation (LLPS) and synaptic clustering. Recombinant G134R-gephyrin variant forms lower oligomers and retains only 60% of its molybdenum cofactor (Moco) synthesis activity while binding to glycine receptor models is unaffected. In non-neuronal cells, G134R fails to oligomerize beyond dimers with Moco synthesis activity reduced to 5%. In neurons, G134R is unable to form synaptic clusters and exerts a dominant-negative effect on WT-gephyrin, severely disrupting inhibitory synapse formation. Our findings highlight a critical role for the G-domain in gephyrin self-assembly and LLPS, shifting the focus from the E-domain-centric view of gephyrin function and providing a novel molecular mechanism for epilepsy linked to G-domain mutations.

Indexed as

Carrier ProteinsEpilepsyMembrane ProteinsProtein MultimerizationAnimalsHumansMetalloproteinsMolybdenum CofactorsMutation, MissenseNeuronsPhase SeparationProtein DomainsReceptors, GlycineCarrier ProteinsgephyrinMembrane ProteinsMetalloproteinsMolybdenum CofactorsmolybdopterinReceptors, Glycine

Identifiers

PMID42380307
PMCPMC13470343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.